Latest Content

Delving Into Clinical Research For Patients With Breast Cancer

February 26th 2025, 4:12pm

By Alex Biese

Video

Dr. Yuan Yuan breaks down studies for patients with breast cancer, such as the phase 3 CompassHER2 RD Trial.

Clinical Trials to Watch in Triple-Negative Breast Cancer

February 26th 2025, 4:03pm

By Alex Biese

Video

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

FDA Accepts sBLA For Opdivo Plus Yervoy For Some Patients with mCRC

February 26th 2025, 2:00pm

By Alex Biese

Article

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult and pediatric patients with colorectal cancer.

FDA Accepts NDA For Dordaviprone in H3 K27M-Mutant Diffuse Glioma

February 25th 2025, 10:00pm

By Alex Biese

Article

A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 K27M-mutant diffuse glioma, with a target action date of Aug. 18.

FDA Accepts Priority Review for Pre- and Postsurgical Keytruda in HNSCC

February 25th 2025, 8:00pm

By Alex Biese

Article

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally advanced head and neck cancer.

Treating Lymphedema with a Simple Trinket

February 25th 2025, 6:00pm

By Felicia Mitchell

Article

Buying a pretty bracelet was healing because it let me look at my lymphedema in a new light.

Understanding Biliary Tract Cancer and The Current Standard of Care

February 25th 2025, 5:00pm

By Dr. Rachna Shroff

Video

An expert explains what biliary tract cancers are and the current landscape of treatment as well as future advancements.

Some KRAS Mutations Associated With Worse Outcomes in Pancreatic Cancer

February 25th 2025, 4:00pm

By Dr. Vaia Florou

Article

In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, researchers have found.

Neoadjuvant Opdivo Combo Elicits Statistically Significant OS Findings in Resectable NSCLC

February 25th 2025, 2:00pm

By Ryan Scott

Article

Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus chemo alone in resectable NSCLC.

What Patients With Cancer Should Know About DPD Deficiency Prior to Chemo

February 24th 2025, 10:00pm

By Dr. Gabriel A. Brooks

Video

Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it.

FDA Grants Fast Track Designation to AUTX-703 In R/R AML

February 24th 2025, 8:00pm

By Alex Biese

Article

The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous leukemia.

Colorectal Cancer or Any Type of Cancer Can Test a Friendship

February 24th 2025, 6:00pm

By Joe Bullock

Article

Cancer tested my friendships by showing who could stay present through tough conversations, support me emotionally and endure pain together despite the loss.

GAP Triplet May Be Less Safe Than Doublet Chemo in Biliary Tract Cancer

February 24th 2025, 5:00pm

By Dr. Rachna Shroff

Video

An expert explains that the GAP regimen did not improve overall survival in advanced biliary tract cancer versus the doublet and increased severe side effects.

Zongertinib Receives Priority Review For HER2 Mutant NSCLC

February 24th 2025, 4:00pm

By Spencer Feldman

Article

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive results and favorable safety.

Odronextamab is Safe and Effective in R/R DLBCL After Progression on CAR T

February 24th 2025, 2:00pm

By Ryan Scott

Article

Odronextamab demonstrated a manageable safety profile and generated durable responses in patients with R/R DLBCL who have progressed after CAR-T therapy.